On August 20, 2026, Shenzhen Cell Valley Biopharmaceutical Group Co., Ltd. and Guangdong Sansheng Pharmaceutical Co., Ltd. officially signed a Strategic Partnership Memorandum of Understanding at the Shenzhen Qianhai Shenzhen-Hong Kong Cell Valley conference room. The signing ceremony was attended by Shi Yuanyuan, Chairman and General Manager of the Cell Valley Group, and Lu Honghui, General Manager of Guangdong Sansheng. The two parties will establish a long-term, in-depth strategic partnership in the cell and gene therapy (CGT) field, covering technology R&D, clinical translation, process scale-up, industrial production, platform development, project sourcing, and talent cultivation.

The Cell Valley Group has long been deeply engaged in the CGT field, having built a full-chain technical service system encompassing vector construction, cell process development, GMP manufacturing, quality control, IIT clinical research, translation of emerging biomedical technologies, and IND application support. It has accumulated extensive experience in novel cell therapy technology R&D, including In vivo CAR-T, CAR-NK, and CAR-γδT, as well as hospital-based clinical translation. Guangdong Sansheng, drawing on the industrial foundation of the Sansheng Pharmaceutical Group, possesses mature platform capabilities and quality management systems in antibody development, process scale-up, CGT industrialization, and CDMO production.

Under the terms of the Memorandum of Understanding, both parties will fully leverage their respective advantages across different segments of the industrial chain to establish a synergistic model of "early R&D and clinical translation + process scale-up and industrial production." This collaboration will drive twoway business development for CDMO services, jointly providing hospitals, research institutions, and innovative pharmaceutical companies with one-stop services spanning scientific innovation, proofofconcept, clinical research, and industrial implementation.

Furthermore, the two parties will strengthen the sharing of clinical resources from toptier tertiary hospitals, expert thinktank resources, public research platform resources, and domestic and international project resources. Through joint technical exchanges, academic activities, talent development, and industry standard building, they will continuously enhance technology translation efficiency and industrial service capabilities in the CGT field.

This strategic cooperation marks an important step for the Cell Valley Group in improving its full-chain CGT service system and strengthening its industrial collaboration capabilities. Going forward, both parties will jointly explore more efficient, standardized, and replicable pathways for translating cell and gene therapy achievements—accelerating the journey of innovative technologies from the laboratory to the clinic and from the clinic to industrialization—and contributing to the high-quality development of China's CGT industry.

About Guangdong Sansheng:

Founded in 2016, Guangdong Sansheng is the South China headquarters and R&D center of the Sansheng Pharmaceutical Group, with a total investment exceeding RMB 1.5 billion and covering an area of 116.16 mu. The company is committed to providing an open, integrated technology service platform, focusing on four strategic areas: biologics, cell and gene therapy, consumer healthcare, and health management. It offers fulllifecycle services covering from preclinical R&D to commercial production. Leveraging its modular technology platforms (prokaryotic/eukaryotic/cell expression systems), the company undertakes process development, analytical method validation, and cGMP production for recombinant proteins, cytokines, peptides, nucleic acid drugs, and cell therapy products, dedicated to providing customized solutions that meet regulatory standards in China, the United States, and Europe for innovative therapies.